Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
Asim Amin(Johns Hopkins University), Hans J. Hammers(Southwestern Medical Center), Jennifer L. Spratlin(University of Alberta), Brian I. Rini(Vanderbilt University Medical Center), Elizabeth R. Plimack(Fox Chase Cancer Center), Sumanta K. Pal(City of Hope), John F. Kurland(AstraZeneca (Netherlands)), Jennifer J. Knox(National Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Christian Kollmannsberger(BC Cancer Agency), Marc S. Ernstoff(National Cancer Institute), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Yun Shen(Bristol-Myers Squibb (United States)), Jeffrey R. Infante(Cancer Research Center), Paul Gagnier(Bristol-Myers Squibb (United States)), Daniel Yick Chin Heng(University of Calgary), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 233
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k